Skip to main content

Table 4 Changes in individual REVEAL components at ≥6-month time point

From: Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study

ComponentnBaseline score, mean (SD)≥6-month score, mean (SD)Mean change (95% CI)p-value
WHO FC (as continuous)722.1 (0.7)2.8 (0.7)−0.7 (−0.8, −0.5)< 0.0001
SBP, mm Hg72120.4 (17.1)117.9 (15.6)−2.5 (−6.4, 1.4)0.0476
Heart rate, beats/min7377.8 (12.1)77.0 (13.8)−0.8 (−4.3, 2.8)0.5057
6-min walk test, m46364.5 (133.3)406.3 (112.3)41.8 (14.5, 69.2)0.0003
BNP, pg/mL16310.1 (350.2)152.5 (164.8)−157.6 (− 336.3, −21.1)0.0229
NT-proBNP, pg/mL371121.1 (1497.4)590.6 (630.4)−530.0 (− 972.0, −88.9)0.0014
DLCO, % predicted2352.7 (18.0)50.8 (19.2)−1.9 (− 1.6, 5.5)0.2753
mRAP, mm Hg127.9 (4.0)7.7 (2.6)−0.3 (−1.6, 2.1)0.4939
PVR, WU1311.5 (4.6)8.1 (3.4)−3.4 (−6.5, −0.2)0.0033
  1. Significant p-values are marked in bold
  2. BNP brain natriuretic peptide, CI confidence interval, DLCO diffusing capacity of the lungs for carbon monoxide, FC functional class, mRAP mean right atrial pressure, NT-proBNP N-terminal pro-BNP, PAH pulmonary arterial hypertension, PVR pulmonary vascular resistance, Q1 25th percentile, Q3 75th percentile, SD standard deviation, SBP systolic blood pressure, WHO World Health Organization, WU Wood units